Hylomorph secures a CHF 5.2 million Series-B round led by Geneva Smart Invest and Start Angels Network
03.12.2021
Hylomorph, a rapidly growing clinical-stage medtech startup with a history of national and international recognition, completed a CHF 5.2 million Series-B financing round. At the same time, the company attracted CHF 0.9 million in new non-dilutive funding. Hylomorph was a Venture Leader in 2015 and a Venture Kick winner in 2016.
 The Hylomorph founding and management team
|
 |
These “booster injections” aim at safely bringing the company to FDA and CE mark approval of its product portfolio, beginning with the blockbuster Hylomate®. The existing investors made a strong statement with their continued support by co-leading the financing round with Geneva Smart Invest (GSI) and the Start Angels Network (SAN), including, among others, Verve Ventures and Zürcher Kantonalbank (ZKB). The Series-B investor syndicate was further strengthened by EFI Lake Geneva Ventures, the Geneva-based fund targeting Swiss innovation.
“We are proud of this outstanding result, obtained in challenging times, confirming the strong trust base established with investors,” said Dr. Simone Bottan, CEO and founder of Hylomorph. “Our clinical development program is progressing very well, and results are extremely encouraging. The new funding will carry us to market clearance for the US and EU. Our work aims at paving a future where postoperative complications in medical implants are tamed and suppressed, combining benefits in patients’ quality of life, clinician quality-of-care, and healthcare cost efficiency. Our goal is in sight.”
“The mission, team, technology, and attractive market painted a picture which left no doubts for our investment in Hylomorph,” said Erich Platzer MD PhD, recent president of SAN, longstanding business angel, and VC investor. “Over time, the market approach and growth strategy have been confirmed by multiple experts. The plan execution is in the hands of a strong management team. We expect Hylomorph to become an impressive success story.”
The Hylomorph founding and management team (from left to right): Simone Bottan (CEO), Francesco Robotti (COO), Sonia Schmocker (Chief Regulatory and Quality Officer), and Aldo Ferrari (CSO)
Source: Hylomorph press release (text) and website (photos)
“We are proud of this outstanding result, obtained in challenging times, confirming the strong trust base established with investors,” said Dr. Simone Bottan, CEO and founder of Hylomorph. “Our clinical development program is progressing very well, and results are extremely encouraging. The new funding will carry us to market clearance for the US and EU. Our work aims at paving a future where postoperative complications in medical implants are tamed and suppressed, combining benefits in patients’ quality of life, clinician quality-of-care, and healthcare cost efficiency. Our goal is in sight.”
“The mission, team, technology, and attractive market painted a picture which left no doubts for our investment in Hylomorph,” said Erich Platzer MD PhD, recent president of SAN, longstanding business angel, and VC investor. “Over time, the market approach and growth strategy have been confirmed by multiple experts. The plan execution is in the hands of a strong management team. We expect Hylomorph to become an impressive success story.”
The Hylomorph founding and management team (from left to right): Simone Bottan (CEO), Francesco Robotti (COO), Sonia Schmocker (Chief Regulatory and Quality Officer), and Aldo Ferrari (CSO)Source: Hylomorph press release (text) and website (photos)